Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) Price Target at $40.22 (2024)

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given an average rating of “Moderate Buy” by the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $40.22.

A number of equities research analysts have issued reports on DNLI shares. Stifel Nicolaus cut their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a research note on Wednesday, May 8th. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of Denali Therapeutics in a research note on Wednesday, May 8th. Wedbush lowered their target price on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. The Goldman Sachs Group decreased their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Finally, UBS Group reduced their price objective on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 9th.

View Our Latest Stock Analysis on DNLI

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $18.56 on Thursday. The stock has a fifty day moving average of $18.39 and a 200 day moving average of $18.88. The stock has a market cap of $2.65 billion, a PE ratio of -19.33 and a beta of 1.39. Denali Therapeutics has a one year low of $14.56 and a one year high of $33.31.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter last year, the firm earned ($0.80) earnings per share. As a group, sell-side analysts predict that Denali Therapeutics will post -2.78 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Steve E. Krognes sold 92,500 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the transaction, the director now owns 47,341 shares of the company’s stock, valued at $970,490.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares in the company, valued at $2,159,006.47. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Steve E. Krognes sold 92,500 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the transaction, the director now owns 47,341 shares in the company, valued at approximately $970,490.50. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Denali Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company’s stock worth $225,069,000 after buying an additional 133,810 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Denali Therapeutics by 3.6% during the 3rd quarter. Wellington Management Group LLP now owns 7,288,960 shares of the company’s stock worth $150,371,000 after acquiring an additional 250,784 shares in the last quarter. Capital Research Global Investors increased its stake in shares of Denali Therapeutics by 107.9% in the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock valued at $124,145,000 after purchasing an additional 3,140,429 shares in the last quarter. Baker BROS. Advisors LP boosted its position in Denali Therapeutics by 43.1% during the first quarter. Baker BROS. Advisors LP now owns 3,731,695 shares of the company’s stock worth $76,574,000 after purchasing an additional 1,124,499 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in Denali Therapeutics by 27.1% in the 3rd quarter. Federated Hermes Inc. now owns 1,351,900 shares of the company’s stock valued at $27,890,000 after acquiring an additional 288,400 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

(Get Free Report

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Featured Articles

• Five stocks we like better than Denali Therapeutics
• Consumer Staples Stocks, Explained
• MarketBeat Week in Review – 5/27 – 5/31
• What is the S&P/TSX Index?
• Foot Locker’s Quarter Sends Doubters Running
• What is the Australian Securities Exchange (ASX)
• Costco Wholesale Can Hit New Highs; A Rebound Is Coming

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.